Bio-Rad Laboratories (NYSE:BIO) Given New $330.00 Price Target at Wells Fargo & Company

Bio-Rad Laboratories (NYSE:BIO) had its price target raised by investment analysts at Wells Fargo & Company from $310.00 to $330.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the medical research company’s stock. Wells Fargo & Company‘s target price would suggest a potential downside of 3.92% from the company’s previous close.

Several other analysts also recently issued reports on the stock. Royal Bank Of Canada began coverage on shares of Bio-Rad Laboratories in a research note on Friday, May 15th. They set an “outperform” rating and a $320.00 target price on the stock. Zacks Research cut Bio-Rad Laboratories from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Citigroup downgraded Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and lowered their price target for the company from $375.00 to $300.00 in a report on Tuesday, April 7th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Bio-Rad Laboratories in a research note on Monday. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus target price of $316.67.

Bio-Rad Laboratories Trading Up 3.2%

BIO stock traded up $10.60 during mid-day trading on Wednesday, reaching $343.48. 148,109 shares of the stock traded hands, compared to its average volume of 328,071. Bio-Rad Laboratories has a 52-week low of $236.73 and a 52-week high of $352.63. The stock’s fifty day moving average is $301.02 and its 200-day moving average is $287.81. The company has a market cap of $9.19 billion, a P/E ratio of 56.59 and a beta of 1.06. The company has a current ratio of 3.21, a quick ratio of 2.37 and a debt-to-equity ratio of 0.12.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Tuesday, August 4th. The medical research company reported $2.62 earnings per share for the quarter, topping the consensus estimate of $1.75 by $0.87. The business had revenue of $651.00 million for the quarter, compared to the consensus estimate of $623.99 million. Bio-Rad Laboratories had a net margin of 6.52% and a return on equity of 3.56%. The firm’s quarterly revenue was down .1% compared to the same quarter last year. During the same period last year, the firm posted $2.61 earnings per share. As a group, sell-side analysts expect that Bio-Rad Laboratories will post 9.14 earnings per share for the current year.

Hedge Funds Weigh In On Bio-Rad Laboratories

Institutional investors and hedge funds have recently modified their holdings of the stock. Assenagon Asset Management S.A. raised its holdings in shares of Bio-Rad Laboratories by 57.8% during the second quarter. Assenagon Asset Management S.A. now owns 233,227 shares of the medical research company’s stock worth $68,478,000 after acquiring an additional 85,393 shares in the last quarter. Empowered Funds LLC increased its position in Bio-Rad Laboratories by 38.0% in the 1st quarter. Empowered Funds LLC now owns 2,168 shares of the medical research company’s stock worth $604,000 after purchasing an additional 597 shares during the last quarter. Amundi increased its position in Bio-Rad Laboratories by 1,763.4% in the 1st quarter. Amundi now owns 38,778 shares of the medical research company’s stock worth $10,809,000 after purchasing an additional 36,697 shares during the last quarter. California State Teachers Retirement System raised its stake in shares of Bio-Rad Laboratories by 22.9% during the 1st quarter. California State Teachers Retirement System now owns 21,932 shares of the medical research company’s stock worth $6,114,000 after purchasing an additional 4,082 shares in the last quarter. Finally, Royal Bank of Canada raised its stake in shares of Bio-Rad Laboratories by 16.9% during the 1st quarter. Royal Bank of Canada now owns 17,198 shares of the medical research company’s stock worth $4,794,000 after purchasing an additional 2,487 shares in the last quarter. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Rad Laboratories News Roundup

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Q2 earnings topped expectations. Bio-Rad reported adjusted earnings of $2.62 per share, well above the $1.75 consensus estimate cited by MarketBeat and the $2.34 estimate from Zacks. Earnings were also slightly higher than the $2.61 reported a year earlier. Bio-Rad Laboratories Beats Q2 Earnings Estimates
• Positive Sentiment: Revenue and cash flow exceeded forecasts. Quarterly revenue was $651 million, above the approximately $624 million analyst estimate, while operating cash flow reached $98.7 million. Cash and equivalents increased to $517 million, supporting the company’s balance-sheet flexibility. Bio-Rad Laboratories Earnings Report
• Neutral Sentiment: Growth remained essentially flat. Revenue declined 0.1% year over year, although gross profit improved modestly to $345.8 million. Operating profit eased to $72.6 million, indicating that the earnings beat did not come from strong top-line growth. Bio-Rad Laboratories Second-Quarter Results
• Negative Sentiment: Restructuring creates near-term uncertainty. Bio-Rad plans to cut jobs and close facilities, a move intended to reduce costs but also signaling pressure on operations and demand. Details on the scale and financial impact of the actions may remain a focus for investors. Bio-Rad Laboratories to Cut Jobs and Close Facilities
• Negative Sentiment: Full-year revenue guidance was cautious. Bio-Rad forecast fiscal 2026 revenue of $2.5 billion to $2.6 billion, slightly below the roughly $2.6 billion consensus estimate. With the stock trading near its 52-week high and at an elevated valuation, investors appear to be demanding stronger growth, limiting the positive reaction to the earnings beat.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.